Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19200045 | METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | May 2025 | March 2026 | Abandon | 10 | 1 | 0 | No | No |
| 19044943 | INSECT NEUROPEPTIDES 8 | February 2025 | October 2025 | Allow | 8 | 1 | 1 | No | No |
| 18444111 | MODIFIED U6 PROMOTER SYSTEM FOR TISSUE SPECIFIC EXPRESSION | February 2024 | September 2025 | Abandon | 19 | 0 | 1 | No | No |
| 18441502 | METHODS AND COMPOSITIONS FOR DETERMINING PLOIDY | February 2024 | February 2026 | Allow | 24 | 1 | 1 | Yes | No |
| 18412406 | NEW METHODS AND SYSTEMS FOR TARGETED GENE MANIPULATION | January 2024 | January 2026 | Allow | 24 | 1 | 1 | No | No |
| 18521884 | GENERATION OF NEURAL STEM CELLS FROM HUMAN TROPHOBLAST STEM CELLS | November 2023 | November 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18505163 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) | November 2023 | September 2025 | Allow | 22 | 1 | 0 | No | No |
| 18502536 | COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY | November 2023 | April 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18494883 | FACTOR H VARIANTS FOR TREATMENT OF DISEASE | October 2023 | October 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18492050 | INSECT NEUROPEPTIDES 8 | October 2023 | October 2024 | Allow | 12 | 1 | 2 | Yes | No |
| 18467952 | Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic Cells | September 2023 | September 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18242406 | Hard Tissue Therapeutics | September 2023 | January 2026 | Allow | 28 | 1 | 1 | Yes | No |
| 18115847 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | August 2023 | October 2025 | Abandon | 31 | 1 | 1 | No | No |
| 18454780 | METHODS AND COMPOSITIONS FOR EGG WHITE PROTEIN PRODUCTION | August 2023 | March 2025 | Abandon | 19 | 2 | 1 | Yes | No |
| 18233216 | Method for Predicting and Treating Clinically Significant Prostate Cancer | August 2023 | July 2025 | Abandon | 24 | 2 | 0 | No | No |
| 18347342 | COMPOSITION FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTS | July 2023 | March 2025 | Allow | 20 | 1 | 0 | No | No |
| 18345183 | METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR | June 2023 | July 2024 | Abandon | 13 | 1 | 0 | Yes | No |
| 18345191 | Method of Increasing the Function of an AAV Vector | June 2023 | August 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18337160 | TRANSPOSASE-MEDIATED IMAGING OF THE ACCESSIBLE GENOME | June 2023 | February 2026 | Allow | 32 | 2 | 0 | Yes | No |
| 18324843 | TRANSGENIC BACTERIA WITH EXPANDED AMINO ACID USAGE AND NUCLEIC ACID MOLECULES FOR USE IN THE SAME | May 2023 | February 2025 | Allow | 21 | 1 | 0 | No | No |
| 18200595 | METHODS OF TREATING AN ISCHEMIC DISEASE | May 2023 | August 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18315332 | EARLY POST-TRANSFECTION ISOLATION OF CELLS (EPIC) FOR BIOLOGICS PRODUCTION | May 2023 | March 2026 | Abandon | 34 | 3 | 0 | No | No |
| 18314050 | COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOF | May 2023 | March 2024 | Allow | 10 | 5 | 0 | Yes | Yes |
| 18313482 | Engineered Guide RNA Sequences for In Situ Detection and Sequencing | May 2023 | December 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18143547 | MDCK SUSPENSION CELL LINES IN SERUM-FREE, CHEMICALLY-DEFINED MEDIA FOR VACCINE PRODUCTION | May 2023 | March 2026 | Allow | 35 | 4 | 0 | Yes | No |
| 18139661 | AAV-MEDIATED EXPRESSION USING A SYNTHETIC PROMOTER AND ENHANCER | April 2023 | May 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18296446 | Orthogonal Cas9 Proteins for RNA-Guided Gene Regulation and Editing | April 2023 | November 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 18169473 | TREATMENT FOR DISEASES CAUSED BY RNA VIRUS SARS-COV-2 | February 2023 | November 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 18169368 | COLLAGEN 7 COMPOSITIONS AND METHODS OF USING THE SAME | February 2023 | November 2025 | Abandon | 33 | 1 | 1 | No | No |
| 18165138 | METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR | February 2023 | December 2023 | Abandon | 11 | 1 | 0 | No | No |
| 18040684 | TWO COMPONENT CO-ASSEMBLING TWO DIMENSIONAL PROTEIN STRUCTURES | February 2023 | March 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18156215 | EXPRESSION OF FC-CONTAINING PROTEINS | January 2023 | June 2025 | Allow | 29 | 2 | 1 | No | No |
| 18014530 | HEPARANASE-NEUTRALIZING A54 MONOCLONAL ANTIBODY | January 2023 | December 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 18069651 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | December 2022 | December 2025 | Abandon | 36 | 2 | 1 | No | No |
| 18080093 | Methods and Compositions for Rapid Generation of Single and Multiplexed Reporters in Cells | December 2022 | September 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 18061000 | METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR | December 2022 | July 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18057398 | Incretin Analogs and Uses Thereof | November 2022 | March 2025 | Allow | 28 | 1 | 1 | No | No |
| 18056823 | PEPTIDE-POLYNUCLEOTIDE-HYALURONIC ACID NANOPARTICLES AND METHODS FOR POLYNUCLEOTIDE TRANSFECTION | November 2022 | March 2026 | Allow | 40 | 3 | 1 | Yes | No |
| 18056708 | METHOD FOR SOLUBLE EXPRESSION AND PURIFICATION OF HYDROPHOBIN | November 2022 | May 2025 | Allow | 30 | 2 | 0 | No | No |
| 18054786 | METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR | November 2022 | January 2025 | Abandon | 26 | 1 | 0 | No | No |
| 17998092 | CHIMERIC ANTIGEN RECEPTOR, MACROPHAGE EXPRESSING SAME, METHOD FOR ADJUSTING MACROPHAGE POLARIZATION, AND USE THEREOF | November 2022 | October 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 18049593 | MODIFICATION OF RNA, PRODUCING AN INCREASED TRANSCRIPT STABILITY AND TRANSLATION EFFICIENCY | October 2022 | May 2025 | Allow | 30 | 3 | 2 | Yes | No |
| 18047953 | METHODS AND COMPOSITIONS FOR EGG WHITE PROTEIN PRODUCTION | October 2022 | February 2025 | Abandon | 28 | 1 | 1 | No | No |
| 17919020 | Treatment for Diseases Caused by RNA Viruses | October 2022 | October 2025 | Abandon | 36 | 1 | 1 | No | No |
| 17918096 | PEPTIDES AND USES THEREOF | October 2022 | December 2025 | Abandon | 38 | 1 | 0 | Yes | No |
| 17915429 | METHOD OF TREATING CORONAVIRUS INFECTIONS | September 2022 | December 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17936377 | 3'-UTR SEQUENCES FOR STABILIZATION OF RNA | September 2022 | July 2025 | Allow | 33 | 1 | 1 | Yes | No |
| 17934661 | PROCESSES AND AGENTS FOR GLAUCOMA | September 2022 | November 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17821713 | METHODS FOR TREATING PULMONARY DISEASE USING INTER-ALPHA INHIBITOR PROTEINS | August 2022 | February 2025 | Allow | 30 | 1 | 0 | Yes | No |
| 17879291 | METHOD FOR PRODUCING HYDROLYSED KERATINACEOUS MATERIAL | August 2022 | August 2025 | Allow | 37 | 2 | 0 | No | No |
| 17811626 | DIRECTED EDITING OF CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9 | July 2022 | July 2024 | Allow | 24 | 1 | 0 | No | No |
| 17855932 | Therapeutic APAC Molecule comprising Heparin Conjugated to a Plasma Protein | July 2022 | September 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17845169 | METHODS AND COMPOSITIONS FOR DETERMINING PLOIDY | June 2022 | January 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17749731 | Compositions Comprising Antimicrobial Peptides | May 2022 | February 2024 | Allow | 21 | 3 | 1 | Yes | No |
| 17748495 | Materials and Methods for Treatment of Duchenne Muscular Dystrophy | May 2022 | February 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 17777159 | A SYNERGISTIC FORMULATION FOR MANAGEMENT OF RESPIRATORY PATHOGENS INCLUDING CORONAVIRUSES | May 2022 | March 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17743526 | Polypeptide Containing DNA-Binding Domain | May 2022 | March 2025 | Allow | 34 | 2 | 1 | Yes | No |
| 17729751 | MODIFIED U6 PROMOTER SYSTEM FOR TISSUE SPECIFIC EXPRESSION | April 2022 | November 2023 | Allow | 19 | 0 | 0 | Yes | No |
| 17692807 | Methods of Treating Disease by Skewing Macrophage Phenotype with Alternating Electric Fields | March 2022 | July 2025 | Allow | 40 | 3 | 1 | Yes | No |
| 17692925 | AAV DELIVERY OF NUCLEOBASE EDITORS | March 2022 | February 2026 | Allow | 48 | 3 | 1 | Yes | No |
| 17753423 | POLYPEPTIDE MONOLAYER WITH HIGH POTENTIAL AND SUPER-HYDROPHILICITY, AND PREPARATION METHOD AND APPLICATION THEREOF | March 2022 | January 2026 | Abandon | 47 | 2 | 1 | No | No |
| 17677827 | METHODS OF TREATING OR PREVENTING PYRUVATE KINASE DEFICIENCY | February 2022 | July 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17672744 | RNA-Guided Human Genome Engineering | February 2022 | September 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17634178 | THERAPEUTIC PEPTIDES | February 2022 | October 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17590737 | INDUCIBLE EXPRESSION FROM TRANSPOSON-BASED VECTORS AND USES | February 2022 | April 2023 | Allow | 14 | 0 | 0 | Yes | No |
| 17589547 | Compositions for Treatment of Vascular Disease | January 2022 | June 2024 | Allow | 28 | 2 | 0 | No | No |
| 17630994 | DNA-AFFIBODY-DRUG NANOPARTICLES FOR INHIBITING THE METASTASIS OF CANCER CELLS OVEREXPRESSING HER2 | January 2022 | April 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17575488 | RECOMBINANT ADENOVIRUSES CARRYING TRANSGENES | January 2022 | December 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17571550 | METHOD FOR TREATING COLORECTAL CANCER | January 2022 | April 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17568183 | TYPE VI-E AND TYPE VI-F CRISPR-CAS SYSTEM AND USES THEREOF | January 2022 | July 2025 | Allow | 42 | 3 | 1 | No | No |
| 17568698 | INSULIN ANALOGS | January 2022 | May 2025 | Allow | 40 | 1 | 1 | No | No |
| 17624523 | INHIBITORS OF IL-15 AND THEIR USE IN TREATING AUTOIMMUNE/INFLAMMATORY DISORDERS | January 2022 | July 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17623748 | STABLE FORMULATIONS OF RECOMBINANT PROTEINS | December 2021 | November 2025 | Allow | 46 | 3 | 1 | Yes | No |
| 17563633 | COMPOSITION FOR TREATMENT OF CRIGLER-NAJJAR SYNDROME | December 2021 | February 2024 | Allow | 26 | 1 | 1 | No | No |
| 17554182 | CONCATEMERIC PEPTIDE EPITOPE RNAS | December 2021 | March 2024 | Allow | 27 | 1 | 0 | Yes | No |
| 17541454 | Methods of Host Cell Modification | December 2021 | May 2025 | Allow | 41 | 3 | 1 | No | No |
| 17541737 | Therapeutic Compositions Directed To Host Mirna For The Treatment Of Sars-Cov-2 (Covid-19) Infection | December 2021 | January 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17614085 | Raw Material Liquid Concentration System | November 2021 | June 2025 | Allow | 42 | 1 | 0 | No | No |
| 17532385 | GENERATION OF NEURAL STEM CELLS FROM HUMAN TROPHOBLAST STEM CELLS | November 2021 | September 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17525344 | Compositions Comprising Antimicrobial Peptides | November 2021 | February 2024 | Allow | 27 | 4 | 1 | Yes | No |
| 17495233 | DEVELOPMENT OF OPTIMIZED RECOMBINANT EXPRESSION CONSTRUCT | October 2021 | July 2024 | Allow | 33 | 3 | 1 | Yes | No |
| 17492229 | ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR | October 2021 | May 2022 | Allow | 8 | 1 | 1 | Yes | No |
| 17599618 | COMBINATION THERAPY TO TREAT CANCER AND USES THEREOF | September 2021 | February 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17478824 | Fc Receptor-ACE2 Conjugates and Use Thereof | September 2021 | September 2024 | Abandon | 36 | 2 | 1 | No | No |
| 17447974 | CELL LINES EXPRESSING INSERTED SECRETABLE REPORTER GENES AT MULTIPLE STAGES OF DIFFERENTIATION | September 2021 | August 2024 | Abandon | 35 | 2 | 0 | No | No |
| 17477918 | Hard Tissue Therapeutics | September 2021 | August 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17437216 | METHODS OF IMPROVING FISH FEED CONVERSION RATE AND SURVIVAL | September 2021 | February 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17404286 | GENE EDITING THROUGH MICROFLUIDIC DELIVERY | August 2021 | February 2024 | Allow | 30 | 1 | 0 | Yes | No |
| 17427370 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | July 2021 | January 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17382855 | SKIN SOOTHING COMPOSITION INCLUDING EXOSOMES DERIVED FROM NATURAL EXTRACT | July 2021 | June 2025 | Abandon | 47 | 6 | 1 | Yes | No |
| 17417587 | ENGINEERED LYSIN-HUMAN DEFENSIN PROTEIN | June 2021 | January 2026 | Allow | 55 | 3 | 0 | Yes | No |
| 17319289 | DETECTION OF NUCLEIC ACIDS | May 2021 | September 2025 | Abandon | 52 | 4 | 1 | No | No |
| 17245437 | METHODS FOR SCARLESS INTRODUCTION OF TARGETED MODIFICATIONS INTO TARGETING VECTORS | April 2021 | July 2022 | Allow | 15 | 2 | 1 | Yes | No |
| 17236660 | ARTIFICIALLY-MANIPULATED NEOVASCULARIZATION REGULATORY SYSTEM | April 2021 | March 2024 | Allow | 34 | 1 | 1 | No | No |
| 17284299 | APOM-FC FUSION PROTEINS FOR TREATING LUNG DISEASES | April 2021 | May 2025 | Allow | 49 | 3 | 0 | Yes | No |
| 17281796 | COMPOSITIONS AND METHODS FOR PREVENTION AND REDUCTION OF METASTASIS | March 2021 | August 2025 | Abandon | 53 | 2 | 1 | No | No |
| 17204412 | THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND A STEROID FOR THE PROPHYLAXIS OF BPD | March 2021 | December 2025 | Allow | 57 | 6 | 0 | Yes | No |
| 17204782 | THERMAL BIOSWITCHES AND RELATED GENETIC CIRCUITS, VECTORS, CELLS, COMPOSITIONS, METHODS AND SYSTEMS | March 2021 | September 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17196504 | COMPOSITIONS FOR TREATMENT OF VASCULAR DISEASE | March 2021 | December 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 17190954 | EXPRESSION FROM TRANSPOSON-BASED VECTORS AND USES | March 2021 | March 2023 | Allow | 25 | 0 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HIBBERT, CATHERINE S.
With a 75.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HIBBERT, CATHERINE S works in Art Unit 1658 and has examined 216 patent applications in our dataset. With an allowance rate of 82.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 46 months.
Examiner HIBBERT, CATHERINE S's allowance rate of 82.9% places them in the 56% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by HIBBERT, CATHERINE S receive 2.69 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by HIBBERT, CATHERINE S is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +41.4% benefit to allowance rate for applications examined by HIBBERT, CATHERINE S. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 26.9% of applications are subsequently allowed. This success rate is in the 46% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 30.2% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 83.3% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 70.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 74.7% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.1% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.